ORAMED PHARMACEUTICALS INC. (ORMP) Gross Margin
- Gross margin · 12 months: Value 0.65%; Formula and calculation Gross profit / revenue. Period ending 2025-12-31..
Gross margin
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 0.65% | Gross profit / revenue. Period ending 2025-12-31. $13.00K ÷ $2.00M × 100 ≈ 0.65% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 13.00K USD | Gross Profit |
| Revenue | 2.00M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2025-12-31 | $13.00K | $2.00M | (m) | 0.65% |
| 2025-09-30 | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.34M | (m) | (m) |
| 2023-09-30 | (m) | $2.02M | (m) | (m) |
| 2023-06-30 | (m) | $2.70M | (m) | (m) |
| 2023-03-31 | (m) | $2.70M | (m) | (m) |
| 2022-12-31 | (m) | $2.70M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) |
| 2021-11-30 | (m) | $2.70M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-08-31 | (m) | $2.70M | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-05-31 | (m) | $2.70M | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2021-02-28 | (m) | $2.70M | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) |
| 2020-11-30 | (m) | $2.71M | (m) | (m) |
| 2020-08-31 | (m) | $2.71M | (m) | (m) |
| 2020-05-31 | (m) | $2.71M | (m) | (m) |
| 2020-02-29 | (m) | $2.71M | (m) | (m) |
| 2019-11-30 | (m) | $2.70M | (m) | (m) |
| 2019-08-31 | (m) | $2.70M | (m) | (m) |
| 2019-05-31 | (m) | $2.64M | (m) | (m) |
| 2019-02-28 | (m) | $2.57M | (m) | (m) |
| 2018-11-30 | (m) | $2.51M | (m) | (m) |
| 2018-08-31 | (m) | $2.45M | (m) | (m) |
| 2018-05-31 | (m) | $2.45M | (m) | (m) |
| 2018-02-28 | (m) | $2.45M | (m) | (m) |
| 2017-11-30 | (m) | $2.46M | (m) | (m) |
| 2017-08-31 | (m) | $2.46M | (m) | (m) |
| 2017-05-31 | (m) | $-909.00K | (m) | (m) |
| 2017-02-28 | (m) | $1.74M | (m) | (m) |
| 2016-11-30 | (m) | $31.00K | (m) | (m) |
| 2016-08-31 | (m) | $641.00K | (m) | (m) |
| 2016-05-31 | (m) | (m) | (m) | (m) |
| 2016-02-29 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |